and Eisai Co, and a research grant from Chugai Pharmaceutical Co. ... 10 Anders HJ, Vielhauer V. Renal co-morbidity in patients with rheumatic diseases.
Letters
Figure 1 Comparisons of (A) serum alanine aminotransferase (ALT) and (B) hepatitis C virus (HCV) viral load before and after biological therapy by Wilcoxon signed-rank test. Biological treatments were categorised by (C) individual biologics and (D) mechanism of action. Data are mean±1 SEM. HCV viral loads were expressed as log10 of the detected values. *p=0.003 by generalised estimating equation.
Acknowledgements The authors are grateful to the Biostatistics Task Force of Taichung Veterans General Hospital, Taiwan, for assistance with statistical analysis. Contributors All authors made substantial intellectual contributions to the conception of the work, analysis and interpretation of the data, and drafting and revising the manuscript.
5
6
Funding None. Competing interests None.
7
Patient consent Obtained.
8
Ethics approval The Ethics Committee of Taichung Veterans General Hospital. Provenance and peer review Not commissioned; externally peer reviewed.
9
10
To cite Chen Y-M, Chen H-H, Chen Y-H, et al. Ann Rheum Dis 2015;74:626–627.
Ennishi D, Terui Y, Yokoyama M, et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008;83:59–62. Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010;116:5119–25. Lin KM, Lin JC, Tseng WY, et al. Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. J Microbiol Immunol Infect 2013;46:65–7. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631–7. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625–39. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010;116:343–53.
Published Online First 1 December 2014 Ann Rheum Dis 2015;74:626–627. doi:10.1136/annrheumdis-2014-206711
REFERENCES 1
2
3
4
Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63:ii18–24. Brunasso AM, Puntoni M, Gulia A, et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. Rheumatology (Oxford) 2011;50:1700–11. Pompili M, Biolato M, Miele L, et al. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013;19:7867–73. Iannone F, La Montagna G, Bagnato G, et al. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. J Rheumatol 2014;41:286–92.
Ann Rheum Dis March 2015 Vol 74 No 3
Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study) Renal involvement is frequently present in patients with rheumatoid arthritis (RA). Approximately 15–25% of patients with RA have renal insufficiency, defined as a glomerular filtration rate (GFR)
